NSB — Neuroscientific Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$21.82m
- AU$17.28m
- AU$0.63m
Australia Stock Exchange release from NEUROSCIENTIFIC : New data demonstrates EmtinB activity in autoimmune diseases
Australia Stock Exchange release from NEUROSCIENTIFIC : NSB 1HY22 Key Activity Highlights
Australia Stock Exchange release from NEUROSCIENTIFIC : PRE_NR Ends: 10:14:41
Australia Stock Exchange release from NEUROSCIENTIFIC : Half Yearly Report and Accounts
Australia Stock Exchange release from NEUROSCIENTIFIC : PRE_NR Ends: 09:56:51
Australia Stock Exchange release from NEUROSCIENTIFIC : Successful completion of key studies in lead up to Phase I
Australia Stock Exchange release from NEUROSCIENTIFIC : PRE_NR Ends: 08:34:46
Australia Stock Exchange release from NEUROSCIENTIFIC : Quarterly Activities/Appendix 4C Cash Flow Report
Australia Stock Exchange release from NEUROSCIENTIFIC : PRE_NR Ends: 17:39:23
NeuroScientific Biopharma rises on positive results for tissue-repair drug
Australia Stock Exchange release from NEUROSCIENTIFIC : Positive results in biomarker characterisation of Emtins
Australia Stock Exchange release from NEUROSCIENTIFIC : PRE_NR Ends: 10:08:53
Australia Stock Exchange release from NEUROSCIENTIFIC : Change of Registry Address
Australia Stock Exchange release from NEUROSCIENTIFIC : Change of Director's Interest Notice
Australia Stock Exchange release from NEUROSCIENTIFIC : Notification regarding unquoted securities - NSB
Australia Stock Exchange release from NEUROSCIENTIFIC : Notification regarding unquoted securities - NSB
Australia Stock Exchange release from NEUROSCIENTIFIC : Investor Webinar Presentation
Australia Stock Exchange release from NEUROSCIENTIFIC : NSB partners with leading diffusion MRI company Imeka
Australia Stock Exchange release from NEUROSCIENTIFIC : Investor Webinar Presentation